Usage of biologic and biosimilar products     

FOI REFERENCE: 24086 FOI DATE: 7^th May 2024    

We are analysing the usage of biologic and biosimilar products within Rheumatology and it would be really helpful if you could please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

• Abatacept [Orencia]                           11
• Adalimumab [Humira]                        34
• Adalimumab Biosimilars                     493
• Apremilast [Otezla]                             0
• Baricitinib [Olumiant]                          5
• Bimekizumab [Bimzelx]                      0
• Certolizumab [Cimzia]                        31
• Etanercept [Enbrel]                            9
• Etanercept Biosimilars                       190
• Filgotinib [Jyseleca]                            9
• Golimumab [Simponi]                         15
• Guselkumab [Tremfya]                       0
• Infliximab [Remicade]                         *
• Infliximab Biosimilars                         37
• Ixekizumab [Taltz]                              *
• Risankizumab [Skyrizi]                       0
• Rituximab [MabThera]                        0
• Rituximab Biosimilars                         50
• Sarilumab [Kevzara]                           5
• Secukinumab [Cosentyx]                   36
• Tocilizumab [Ro Actemra]                  69
• Tocilizumab Biosimilars                     0
• Tofacitinib [Xeljanz]                            8
• Upadacitinib [Rinvoq]                         5
• Ustekinumab [Stelara]                        *

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018